Cost-effectiveness of human papillomavirus vaccination and screening in Spain

European Journal of Cancer

Volumn 46, Issue 16, 2010, Pages 2973-2985

  Diaz, Mireia ^a   De Sanjose, Silvia ^a,c   Ortendahl, Jesse ^b   O'Shea, Meredith ^b   Goldie, Sue J ^b   Bosch, F Xavier ^a   Kim, Jane J ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Cervical cancer screening; Cost effectiveness; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER TEST; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; SPAIN; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; COST-BENEFIT ANALYSIS; CYTOLOGICAL TECHNIQUES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SPAIN; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 78049304658     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.06.016     Document Type: Article

References (46)

1. J. Cuzick, M. Arbyn, and R. Sankaranarayanan Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries Vaccine 26 Suppl. 10 2008 K29 K41
2. M. Arbyn, M. Rebolj, and I.M.C.M. De Kok The challenges of organising cervical screening programmes in the 15 old member states of the European Union Eur J Cancer 45 15 2009 2671 2678
3. Nieminen P. How to organise a successful screening programme; the examples of the Nordic countries. The international papillomavirus educational workshops. Malmö, Sweden; May 8-10 2009. http://webcasts.prous.com/ netadmin/webcast-viewer/Preview.aspx?type=0&lid=7872&pv=1&preview= False&idcl=1.
4. J.J. Kim, G.M. Leung, P.P.S. Woo, and S.J. Goldie Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong J Public Health 26 2 2004 130 137
5. Cervix cancer screening. IARC handbooks on cancer prevention, vol. 10. Lyon, France: IARC Press; 2005.
6. E.L. Franco, J. Cuzick, A. Hildesheim, and S. de Sanjosé Issues in planning cervical cancer screening in the era of HPV vaccination Vaccine 24 Suppl. 3 2006 S/171 S/177 [chapter 20]
7. J. Ferlay, F. Bray, P. Pisani, and D.M. Parkin GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide, IARC cancerbase no. 5, version 2.0 2004 IARC Press Lyon
8. S. de Sanjose, X. Cortés, and C. Méndez Age at sexual initiation and number of sexual partners in the female Spanish population results from the AFRODITA survey Eur J Obstet Gynecol Reprod Biol 140 2 2008 234 240
9. L.M. Puig-Tintoré, X. Castellsagué, and A. Torné Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain J Low Genit Tract Dis 12 2 2008 82
10. A. Anttila, and G. Ronco Working group on the registration and monitoring of cervical cancer screening programmes in the European Union; within the European network for information on cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union Eur J Cancer 45 15 2009 2685 2708
11. Schick A. Budgeting for fiscal space. Organisation for economic co-operation and development, 29th annual meeting of senior budget officials, Vienna, Austria; 2008. http://www.oecd.org.
12. S.J. Goldie, J.D. Goldhaber-Fiebert, and G.P. Garnett Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling Vaccine 24 Suppl. 3 2006 S3/155-63 [chapter 18]
13. S.J. Goldie, J.J. Kim, and K. Kobus Cost-effectiveness of HPV 16, 18 vaccination in Brazil Vaccine 25 33 2007 6257 6270
14. J.J. Kim, K.M. Kuntz, and N.K. Stout Multiparameter calibration of a natural history model of cervical cancer Am J Epidemiol 166 2 2007 137 150
15. J.D. Goldhaber-Fiebert, N.K. Stout, and J. Ortendahl Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination Popul Health Metr 5 2007 11
16. V.M. Coupé, J. van Ginkel, and H.E. de Melker HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness Int J Cancer 124 4 2009 970 978
17. C. Bergeron, N. Largeron, R. McAllister, P. Mathevet, and V. Remy Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France Int J Technol Assess Health Care 24 1 2008 10 19 (Pubitemid 351158538)
18. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 2004 437 452
19. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health; 2001.
20. J.A. Sacristán, J. Oliva, J. del Llano, L. Prieto, and J.L. Pinto What is an efficient health technology in Spain? Gac Sanit 16 4 2002 334 343
21. N. Muñoz, F.X. Bosch, and S. de Sanjosé Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 6 2003 518 527 (Pubitemid 36159887)
22. S. de Sanjose, R. Almirall, and B. Lloveras Cervical human papillomavirus infection in the female population in Barcelona, Spain Sex Transm Dis 30 10 2003 788 793
23. J. Dillner, M. Rebolj, and P. Birembaut Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study BMJ 337 2008 a1754
24. F.X. Bosch, N. Muñoz, and S. de Sanjosé Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia Cancer Epidemiol Biomarkers Prev 2 5 1993 415 422
25. F.X. Bosch, M.M. Manos, and N. Muñoz Prevalence of human papillomavirus in cervical cancer: a worldwide perspective JNCI 87 11 1995 796 802
26. M. Bernal, I. Burillo, and J.I. Mayordomo Human papillomavirus (HPV) infection and intraepithelial neoplasia and invasive cancer of the uterine cervix: a case-control study in Zaragoza, Spain Infect Agent Cancer 29 2008 3 8
27. J.A. Rodriguez, F. Barros, A. Carracedo, and C.M. Mugica-van Herckenrode Low incidence of microsatellite instability in patients with cervical carcinomas Diagn Mol Pathol 7 5 1998 276 282
28. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer incidence in five continents, vol. I to VIII. Lyon: IARC CancerBase No. 7; 2005.
29. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. Cancer incidence in Spain (1998-2002). Cancer incidence in five continents, vol. IX. IARC Scientific Publications No. 160, Lyon: IARC; 2007.
30. A.A. Stinnett, and D.A. Paltiel Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means Med Decis Making 17 1997 483 489
31. B. Rash, P. Martin-Hirsch, and A. Schneider Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries Eur J Gynaecol Oncol 29 3 2008 225 232
32. Wright T. Cervical screening in populations vaccinated against HPV. The international papillomavirus educational workshops. Malmö, Sweden; May 8-10; 2009. http://webcasts.prous.com/netadmin/webcast-viewer/Preview.aspx?type= 0&lid=7879&pv=1&preview=False&idcl=1.
33. World Health Statistics. World health organization; 2008. http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf.
34. T.D. Szucs, N. Largeron, K.J. Dedes, R. Rafia, and S. Bénard Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland Curr Med Res Opin 24 5 2008 1473 1483 (Pubitemid 351741581)
35. M. Jit, Y.H. Choi, and W.J. Edmunds Economic evaluation of human papillomavirus vaccination in the United Kingdom BMJ 337 2008 a769
36. S.L. Kulasingam, S. Benard, R.V. Barnabas, N. Largeron, and E.R. Myers Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis Cost Eff Resour Alloc 6 2008 4
37. I. Zechmeister, B. Freiesleben de Blasio, G. Garnett, A.R. Neilson, and U. Siebert Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria Vaccine 27 2009 5133 5141
38. I.M. De Kok, M. van Ballegooijen, and J.D. Habbema Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands J Natl Cancer Inst 101 15 2009 1083 1092
39. J.M. López Alemany, J. Cortés Bordoy, and Á. Gil de Miguel Human papilomavirus tetravalent vaccine cost-effectiveness study Rev Esp Econ Salud 6 7 2007 400 408
40. X. Castellsagué, M. San Martín, J. Cortés, A. González, and V. Remy Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6, 11, 16 y 18 en las enfermedades asociadas al VPH en España Prog Obstet Ginecol 51 9 2008 520 530
41. A. Gauthier, V. Martín-Escudero, and L. Moore Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain Eur J Public Health 18 6 2008 674 680
42. N. Muñoz, R. Manalastas Jr., and P. Pitisuttithum Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial Lancet 373 9679 2009 1949 1957
43. J.T. Schiller, X. Castellsagué, L.L. Villa, and A. Hildesheim An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results Vaccine 26 Suppl. 10 2008 K53 K61 [Review]
44. J. Paavonen, P. Naud, and J. Salmerón Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 9686 2009 301 314
45. S.Y. Kim, J.A. Salomon, and S.J. Goldie Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves Bull World Health Organ 85 11 2007 833 842
46. United Nations (UN), Department of Economic and Social Affairs, Population Division. World population prospects: the 2004 revision. CD-ROM edition-extended dataset. United Nations publications, sales no. E.05.XIII.12. 2005.